Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Gland and Hormone Related Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Uterine Cervical Neoplasms

Carcinoma

Breast Neoplasms

Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Melanoma

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Stomach Neoplasms

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Lung Neoplasms

Carcinoma, Hepatocellular

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Urinary Bladder Neoplasms

Endometrial Neoplasms

Neoplasms, Squamous Cell

Urogenital Neoplasms

Genital Diseases

Urogenital Diseases

Neoplasms by Histologic Type

Skin Diseases

Neoplasms, Glandular and Epithelial

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Uterine Neoplasms

Uterine Diseases

Breast Diseases

Esophageal Cancer

Pancreatic Cancer

Ovarian Cancer

Stomach Cancer

Ovarian Epithelial Cancer

All Drugs and Chemicals

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Groups of patients will receive increasing doses of HMBD-001 as a single agent to find a safe dose that best targets cancer cells. Approximately 26 patients with tumours known to express HER3 will be entered into this arm.

An expansion cohort of up to 25 patients with a confirmed HER3 positive or confirmed NRG1 fusion rearrangement RAS wild type colorectal cancer, castration resistant prostate cancer, triple negative breast cancer or squamous cell head and neck cancer will receive the HMBD-001 single agent RP2D as determined in Part A Arm 1.

Intravenous infusion given over a 21 or 28 day cycle dependent on dosing frequency. Number of cycles: 6 or until disease progression or unacceptable toxicity develops.

HMBD-001

Johann de Bono, Prof

Simon Lord, Dr

Derek Paisley

Johaan de Bono, Prof

This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in patients with advanced HER3 positive solid tumours. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how these can be treated and what happens to HMBD-001 inside the body and how it affects cancer cells.

HMBD-001 is a type of drug called a monoclonal antibody, which works by targeting a protein called HER3, that is found in high numbers in some types of cancers including those which contain NRG1 gene fusions. By attaching itself to this protein it may then work to kill the cancer cells or to stop them growing.

This is a first-in-human clinical trial which has two parts:

Part A is a 'dose escalation' phase where small groups of patients will receive increasing doses of HMBD-001 to find the safest dose which best targets cancer cells.

* In Arm 1, patients will receive HMBD-001 on its own (as a single agent).
* In Arm 2, patients will receive HMBD-001 given with other anti-cancer drugs (in combination).

Part B is a 'dose expansion' phase where larger groups of patients with specific cancer types, known to have high levels of the protein HER3 or a confirmed NRG1 gene fusion will receive the highest doses of HMBD-001 considered to be safe in Part A either alone as single agent or in combination with other anti-cancer drugs.

The main aims of the clinical trial are to find out:

* The highest dose of HMBD-001 alone and in combination with other anti-cancer drugs that can be given safely to patients.
* More about the potential side effects of HMBD-001 when given alone and in combination with other anti-cancer agents and how they can be managed.
* What happens to HMBD-001 inside the body and how it affects cancer cells.
* The potential anti-tumour activity of HMBD-001 as a single agent and in various combination regimens in specific tumour types of HER3 expressing tumours or tumours with NRG1 gene fusions.

HMBD-001 in Advanced HER3 Positive Solid Tumours

HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours

Recommended dose of HMBD-001 given a) as a single agent and b) in combination with selected anticancer agent(s) with an estimated Dose Limiting Toxicity (DLT) rate that is closest to 25% using a one-stage Bayesian Continual Reassessment Method (CRM)

Number of grade 3, 4 and adverse events related to HMBD-001 given a) as a single agent and b) in combination with selected anti-cancer agent(s) graded according to National Cancer Institute Common Criteria for Adverse Events (NCI CTCAE) Version 5.0

Number of patients achieving a complete response (CR) or partial response (PR) to HMBD-001 based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in the chosen tumour types

Maximum observed plasma concentration (Cmax) of HMBD-001

Terminal elimination half-life (t½) of HMBD-001

Time taken to reach maximum observed concentration (Tmax) of HMBD-001

Volume of distribution of HMBD-001 in plasma

Number of patients achieving a complete response (CR), partial response (PR) or stable disease (SD) based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1

Number of Patients whose cancer has not progressed at 12 and 24 months

Number of patients who are still alive at 12 and 24 months

Hummingbird Bioscience

Cancer Research UK

Antineoplastic Agents

Gemcitabine

Paclitaxel

Docetaxel

Albumin-Bound Paclitaxel

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Participants with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring NRG1 gene fusions

Participants with non-small cell lung cancer (NSCLC) harboring NRG1 gene fusions

Participants with other solid tumors harboring NRG1 gene fusions

Participants with solid tumors harboring selected HER3 extracellular mutations

HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

Docetaxel 75 mg/m\^2 IV once every 3 weeks

Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

Nab-paclitaxel

Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

Kon Yew Kwek, BMBCh, DPhil

Nick Pavlakis

Vladimir Andelkovic

Ganessan Kichenadasse

Gary Richardson

Michael Millward

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered to be related to the study treatment.

DLTs will be assessed during the safety run-in phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks for Arm A, 3 weeks for Arm B) of treatment

The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1

Eye Diseases

Symptoms and General Pathology

Heart and Blood Diseases

Ganglion Cysts

Glaucoma

Synovial Cyst

Cysts

Hypertension

Ocular Hypertension

Mucinoses

Connective Tissue Diseases

Oculocerebral Syndrome With Hypopigmentation

Micronutrients

Vasodilator Agents

Lipid Regulating Agents

Hematinics

Vitamins

Niacinamide

Niacin

Nicotinic Acids

Vitamin B Complex

Folic Acid

Trace Elements

Hypolipidemic Agents

Nicotinamide

Nicotinic Acid

Vitamin B3

Folate

Vitamin B9

Group2 Baseline-6week: (Mitovita: 1.0 g/day, QD) 6-12week: (Mitovita: 2.0 g/day, BID) Crossover 12-18week: (Placebo: 1.0 g/day, QD) 18-24week: (Placebo: 2.0 g/day, BID)

Group1 Baseline-6week: (Placebo: 1.0 g/day, QD) 6-12week: (Placebo: 2.0 g/day, BID) Crossover 12-18week: (Mitovita: 1.0 g/day, QD) 18-24week: (Mitovita: 2.0 g/day, BID)

Nicotinamide(Mitovita)

Placebo

Seungsoo Rho, MD, PhD

Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients : Clinical Trial, Cross-over Design, Double-blind, Placebo-control, Randomized, Single-center Study

Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients

Change of PhNR_min(photopic negative response) as measured by Electroretinogram after 12 weeks

Change of PhNR_min(photopic negative response) as measured by Electroretinogram after 6, 12, 18 and 24 weeks

Change of mean deviation as measured by Visual Fields after 12 weeks and 24 weeks

Change of Pointwise sensitivity in glaucomatous eyes as measured by Visual Fields after 12 and 24 weeks: total/pattern deviation

Change of visual field sensitivity number of locations in glaucomatous eyes as measured by Visual Fields after 12 and 24 weeks: total, pattern deviation

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
HMBD-001 in Advanced HER3 Positive Solid Tumours	NCT05057013	Bladder Cancer Triple Negative... Castration-resi... Cervical Cancer RAS Wild Type C... Endometrial Can... Gastric Cancer Hepatocellular ... Melanoma Non-small Cell ... Oesophageal Can... Ovarian Cancer Pancreatic Canc... Squamous Cell C...	HMBD-001	16 Years -	Cancer Research UK
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation	NCT05919537	Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli...	HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine	18 Years -	Hummingbird Bioscience
Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients	NCT06078605	Glaucoma	Nicotinamide(Mi... Placebo	19 Years -	CHA University
Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients	NCT06078605	Glaucoma	Nicotinamide(Mi... Placebo	19 Years -	CHA University
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation	NCT05919537	Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli...	HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine	18 Years -	Hummingbird Bioscience

Spots Global Cancer Trial Database for nrg1

Every month we try and update this database with for nrg1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nrg1

Every month we try and update this database with for nrg1 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nrg1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.